Evidence map›Paper›PMID 39526431›Full record

ArticleThe British journal of nutrition2025

The protective effect of higher serum TAG (51:4) levels against Parkinson's disease.

Yajun Jing, Jinye Su, Honglin Zhu, Yiming Chen, Surmai Shukla, Lianghong Yu, Dengliang Wang, Dezhi Kang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The British journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yajun JingDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou350005, Fujian, People's Republic of China.ORCID 0000-0002-1291-4104
Jinye SuDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou350005, Fujian, People's Republic of China.
Honglin ZhuFaculty of Life Sciences and Medicine, King's College London, London, UK.
Yiming ChenDepartment of Medical Laboratory, College of Medical Technology and Engineering, Fujian Medical University, Fuzhou, Taijiang District, Fuzhou, Fujian350004, People's Republic of China.
Surmai ShuklaDepartment of Immunology, Northwestern University, Evanston, Illinois, USA.
Lianghong YuDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou350005, Fujian, People's Republic of China.
Dengliang WangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou350005, Fujian, People's Republic of China.
Dezhi KangDepartment of Neurosurgery, Neurosurgery Research Institute, The First Affiliated Hospital, Fujian Medical University, Fuzhou350005, Fujian, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence has shown a strong correlation between serum TAG levels, the inflammatory response and Parkinson's disease (PD) onset. However, the causal relationship between TAG levels and PD has not been well established. We aimed to investigate the relationship between serum TAG levels and risk of PD and explore the potential mediating role of circulating immune cells and inflammatory proteins. We utilised genotype data from the GeneRISK cohort, and summary data from genome-wide association studies investigating PD, circulating immune cells, inflammatory proteins and plasma lipidomes. Using Mendelian randomisation (MR) and multivariate MR (MVMR) analysis, we further adjusted for phosphatidylcholine (17:0_18:1) and TAG (58:7). Our results suggested a robust causal link between higher serum TAG (51:4) levels and a decreased risk of PD, with 1 sd genetically instrumented higher serum TAG (51:4) level leading to a 21 per cent (95 % CI 0·66, 0·96) reduction in the risk of PD (

Indexed as

Parkinson DiseaseTriglyceridesAgedFemaleGenome-Wide Association StudyHumansMaleMendelian Randomization AnalysisMiddle AgedPolymorphism, Single NucleotideRisk FactorsTriglyceridesCirculating immune cellsCirculating inflammatory proteinsLipid metabolismMendelian randomisation analysisParkinson’s disease

Identifiers

PMID39526431
PMCPMC12169956

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.